newsfilter
← Latest News
Business Wire·

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included in a planned Phase 2b study in major depressive disorder PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))